Bolt Biotherapeutics, Inc. (BOLT)
4.58
+0.15
(+3.39%)
USD |
NASDAQ |
Jun 11, 09:39
Bolt Biotherapeutics Enterprise Value : 7.729M for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 7.729M |
| June 09, 2026 | 8.094M |
| June 08, 2026 | 8.286M |
| June 05, 2026 | 7.978M |
| June 04, 2026 | 8.363M |
| June 03, 2026 | 8.113M |
| June 02, 2026 | 9.035M |
| June 01, 2026 | 9.420M |
| May 29, 2026 | 9.304M |
| May 28, 2026 | 9.400M |
| May 27, 2026 | 9.36M |
| May 26, 2026 | 9.062M |
| May 22, 2026 | 8.717M |
| May 21, 2026 | 8.026M |
| May 20, 2026 | 8.064M |
| May 19, 2026 | 8.276M |
| May 18, 2026 | 7.585M |
| May 15, 2026 | 8.391M |
| May 14, 2026 | 8.813M |
| May 13, 2026 | 8.487M |
| May 12, 2026 | 8.391M |
| May 11, 2026 | 8.237M |
| May 08, 2026 | 8.180M |
| May 07, 2026 | 8.026M |
| May 06, 2026 | 8.026M |
| Date | Value |
|---|---|
| May 05, 2026 | 8.160M |
| May 04, 2026 | 8.928M |
| May 01, 2026 | 8.928M |
| April 30, 2026 | 8.429M |
| April 29, 2026 | 8.352M |
| April 28, 2026 | 8.506M |
| April 27, 2026 | 8.736M |
| April 24, 2026 | 8.487M |
| April 23, 2026 | 8.372M |
| April 22, 2026 | 9.562M |
| April 21, 2026 | 8.794M |
| April 20, 2026 | 9.101M |
| April 17, 2026 | 8.295M |
| April 16, 2026 | 8.448M |
| April 15, 2026 | 8.640M |
| April 14, 2026 | 8.314M |
| April 13, 2026 | 8.160M |
| April 10, 2026 | 8.640M |
| April 09, 2026 | 7.872M |
| April 08, 2026 | 8.045M |
| April 07, 2026 | 8.391M |
| April 06, 2026 | 8.679M |
| April 02, 2026 | 7.450M |
| April 01, 2026 | 7.872M |
| March 31, 2026 | 6.970M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sangamo Therapeutics, Inc. | 53.47M |
| Arrowhead Pharmaceuticals, Inc. | 9.517B |
| Oncolytics Biotech, Inc. | 87.93M |
| Sarepta Therapeutics, Inc. | 1.979B |
| Anixa Biosciences, Inc. | 63.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.244M |
| Revenue (Quarterly) | 0.026M |
| Total Expenses (Quarterly) | 7.27M |
| EPS Diluted (Quarterly) | -4.311 |
| Gross Profit Margin (Quarterly) | -680.8% |
| Profit Margin (Quarterly) | -27.86K% |
| Earnings Yield | -356.7% |
| Normalized Earnings Yield | -343.59 |